Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
Multiple sclerosis is a progressive demyelinating central nervous system disorder with unknown etiology. The condition has heterogeneous presentations, including relapsing-remitting multiple sclerosis and secondary and primary progressive multiple sclerosis. The genetic and epigenetic mechanisms und...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.980758/full |
| _version_ | 1798019918604533760 |
|---|---|
| author | Sundararajan Jayaraman Arathi Jayaraman |
| author_facet | Sundararajan Jayaraman Arathi Jayaraman |
| author_sort | Sundararajan Jayaraman |
| collection | DOAJ |
| description | Multiple sclerosis is a progressive demyelinating central nervous system disorder with unknown etiology. The condition has heterogeneous presentations, including relapsing-remitting multiple sclerosis and secondary and primary progressive multiple sclerosis. The genetic and epigenetic mechanisms underlying these various forms of multiple sclerosis remain elusive. Many disease-modifying therapies approved for multiple sclerosis are broad-spectrum immunomodulatory drugs that reduce relapses but do not halt the disease progression or neuroaxonal damage. Some are also associated with many severe side effects, including fatalities. Improvements in disease-modifying treatments especially for primary progressive multiple sclerosis remain an unmet need. Several experimental animal models are available to decipher the mechanisms involved in multiple sclerosis. These models help us decipher the advantages and limitations of novel disease-modifying therapies for multiple sclerosis. |
| first_indexed | 2024-04-11T16:49:11Z |
| format | Article |
| id | doaj.art-acee369a4eb0412780cac6ad45f1d9e6 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-11T16:49:11Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-acee369a4eb0412780cac6ad45f1d9e62022-12-22T04:13:30ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-10-011310.3389/fneur.2022.980758980758Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatmentSundararajan Jayaraman0Arathi Jayaraman1Department of Surgery, University of Illinois College of Medicine, Peoria, IL, United StatesXavier University School of Medicine, Oranjestad, ArubaMultiple sclerosis is a progressive demyelinating central nervous system disorder with unknown etiology. The condition has heterogeneous presentations, including relapsing-remitting multiple sclerosis and secondary and primary progressive multiple sclerosis. The genetic and epigenetic mechanisms underlying these various forms of multiple sclerosis remain elusive. Many disease-modifying therapies approved for multiple sclerosis are broad-spectrum immunomodulatory drugs that reduce relapses but do not halt the disease progression or neuroaxonal damage. Some are also associated with many severe side effects, including fatalities. Improvements in disease-modifying treatments especially for primary progressive multiple sclerosis remain an unmet need. Several experimental animal models are available to decipher the mechanisms involved in multiple sclerosis. These models help us decipher the advantages and limitations of novel disease-modifying therapies for multiple sclerosis.https://www.frontiersin.org/articles/10.3389/fneur.2022.980758/fullcentral nervous systemepigeneticsexperimental autoimmune encephalomyelitishistone deacetylasesmultiple sclerosismyelin oligodendrocyte glycoprotein |
| spellingShingle | Sundararajan Jayaraman Arathi Jayaraman Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment Frontiers in Neurology central nervous system epigenetics experimental autoimmune encephalomyelitis histone deacetylases multiple sclerosis myelin oligodendrocyte glycoprotein |
| title | Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment |
| title_full | Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment |
| title_fullStr | Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment |
| title_full_unstemmed | Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment |
| title_short | Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment |
| title_sort | impact of histone modifier induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment |
| topic | central nervous system epigenetics experimental autoimmune encephalomyelitis histone deacetylases multiple sclerosis myelin oligodendrocyte glycoprotein |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.980758/full |
| work_keys_str_mv | AT sundararajanjayaraman impactofhistonemodifierinducedprotectionagainstautoimmuneencephalomyelitisonmultiplesclerosistreatment AT arathijayaraman impactofhistonemodifierinducedprotectionagainstautoimmuneencephalomyelitisonmultiplesclerosistreatment |